Yanhong Liu & Rong Shao. (2024). Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Frontiers Media S.A..
Chicago Style (17th ed.) CitationYanhong Liu and Rong Shao. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A., 2024.
MLA (9th ed.) CitationYanhong Liu and Rong Shao. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Frontiers Media S.A., 2024.
Warning: These citations may not always be 100% accurate.